ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
ESMO 2024 – Keytruda/Lenvima leap... up to a point
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
ESMO 2024 preview – presidential focus
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
Sutro reads the farletuzumab tea leaves
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
